Seres Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 5, 2026
MCRB$1.70-14.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference · Filed/ | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | File No. | Exhibit | FilingDate | FurnishedHerewith |
| 3.1 | Restated Certificate of Incorporation, filed on July 1, 2015 | 8-K | 001-37465 | 3.1 | 7/1/15 | |
| 3.2 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated June 27, 2023 | 8-K | 001-37465 | 3.1 | 6/28/23 | |
| 3.3 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 5, 2024 | 8-K | 001-37465 | 3.1 | 4/8/24 | |
| 3.4 | Certificate of Amendment to Restated Certificate of Incorporation of Seres Therapeutics, Inc., dated April 21, 2025 | 8-K | 001-37465 | 3.1 | 4/22/25 | |
| 3.5 | Amended and Restated Bylaws | 8-K | 001-37465 | 3.1 | 1/2/24 | |
| 10.1 | Non-Employee Director Compensation Program | * | ||||
| 10.2 | Seres Therapeutics, Inc. 2025 Incentive Plan, as amended and restated | S-8 | 333-297341 | 99.1 | 7/9/26 | |
| 10.3 | Amendment No. 1 to Asset Purchase Agreement, dated June 2, 2026, by and between Seres Therapeutics, Inc. and Société des Produits Nestlé S.A. | 8-K | 001-37465 | 10.1 | 6/5/26 | |
| 10.4^ | First Amendment to Lease, dated June 4, 2026, by and between Seres Therapeutics, Inc. and 101 CPD, LLC | 8-K | 001-37465 | 10.2 | 6/5/26 | |
| 10.5 | Third Amendment to Lease and Termination Agreement, dated July 31, 2026, by and between Seres Therapeutics, Inc. and BMR-Sidney Research Campus, LLC | 8-K | 001-37465 | 10.1 | 8/4/26 | |
| 10.6 | Stock Issuance Agreement, dated July 31, 2026, by and between Seres Therapeutics, Inc. and BMR-Sidney Research Campus, LLC | 8-K | 001-37465 | 10.2 | 8/4/26 | |
| 31.1 | Rule 13a-14(a)/15d-14(a) Certification of Interim Chief Executive Officer | * | ||||
| 31.2 | Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer | * | ||||
| 32.1 | Section 1350 Certification of Interim Chief Executive Officer | ** | ||||
| 32.2 | Section 1350 Certification of Chief Financial Officer | ** | ||||
| 101.INS | Inline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document | * | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | * | ||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | * | ||||
- Filed herewith.
** Furnished herewith.
^ Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.